OmniAb, Inc. Overview
Pro stress-test →OmniAb licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable therapeutics discovery. The company's platform creates and screens diverse antibody repertoires to identify optimal antibodies and target-binding proteins for partners' drug development efforts.
Strategic Profile
Pro stress-test →OmniAb's Biological Intelligence platform powers transgenic animal immune systems to create optimized antibody candidates, including proprietary technologies like OmniRat, OmniChicken, OmniMouse, and the newly launched OmniUltra platform. The company operates with 104 active partners, 399 active programs and 32 programs in clinical development or commercialization.
Competitive Landscape
Pro stress-test →OmniAb faces growing competition from alternative antibody discovery and AI-driven platforms that may require higher R&D spending, risking long-term profitability and market share erosion. Key competitors include Genentech/Roche, Regeneron, and emerging AI-powered discovery platforms. OmniAb differentiates through proprietary transgenic animal technologies and expanding AI integration.
Industry Context
OmniAb, Inc. operates in Biotechnology - Antibody & Protein Discovery Platforms.
Key facts
Founded: 2012 · Headquarters: Emeryville, California · Revenue: $18-22M (2025E) · Market cap: $246M